Medeva may be the cure Fisons needs

AFTER MONTHS of bold restructuring that has changed the direction of the company, Fisons is taking its biggest gamble yet. Its plan to take over Medeva, a rival drugs company, is not only a clever strategic move - the entire future of Fisons may also hang on its success.

If it succeeds, the rapid conversion of Fisons from the sick man of the pharmaceuticals sector to a company with a bright future will be complete. If it fails, the restructuring will have left Fisons looking extremely exposed and possibly lacking the expertise to survive in its field.

That the company appears a credible predator for Medeva at all is a tribute to its resurrection. A year ago it was widely seen in the stock market as lacking direction or strategy. Sales were falling and it had few new products in development to make up the shortfall. Almost every large drug company in Europe and the United States had examined it as a takeover target and rejected it. It desperately needed strong medicine to survive.

This is what Stuart Wallis, the chief executive brought in late last year, has provided. In the space of a few weeks he dealt with the loss- making scientific instruments operation by selling it rather than shutting it down. Then, in an almost heretical move for a drugs company, he sold the research and development arm to Astra, the Swedish company, for £202m. The laboratory supplies arm is also expected to be sold.

All of this will raise in the region of £470m in cash for the company while saving it some £70m a year that used to go on research spending. These were the kind of bold decisions that many believe could only have been taken by an outsider to the industry. Mr Wallis was one of the directors involved in changing Bowater, the struggling paper company, into a successful packaging group. He has no background in pharmaceuticals.

What he has done, however, is to turn Fisons from a conventional drugs company researching its own products into one that buys in products and uses its substantial sales force to market them. This strips out the huge development costs of new drugs although it now means the company must find drugs in a late stage of development to "license in" from outside and then market.

But Mr Wallis's restructuring can be seen in another light, too. "It is classic conglomerate financing," says one analyst. "It's the kind of thing Bowater might have done. You write down the assets, sell off the loss-making bits, boost the share price, and then make an acquisition that will improve the earnings per share."

Either way, a link with Medeva makes perfect sense for Fisons. It would not only get its takeover, it would also be buying the company on which it is modelling itself. Medeva, under its chairman, Bernard Taylor, a former Glaxo executive, has grown rapidly as a drug marketing company. It has bought in several successful "late-stage development" drugs, including respiratory drugs and a promising hepatitis B vaccine that is to be marketed soon.

Medeva's sales last year were £239m compared with £450m at Fisons. But while Medeva's sales have soared sixfold in the last five years and growth could reach 20 per cent, Fisons's sales growth is steadily falling into single figures.

Until Fison's transformation, Medeva was virtually the only UK drugs company occupying this niche in the sector. To find, buy in and exploit successful drugs in an increasingly competitive market requires management with long experience of pharmaceuticals and wide contacts in the industry. Led by Mr Taylor, Medeva has this.

Fisons does not. All its experience is focused on research and development rather than buying new drugs on the open market. Capturing Medeva's expertise would solve that at a stroke.

"The easy bit for Fisons was changing the company," says Peter Laing, analyst at Salomon Brothers. "Now it has to survive in its new form. It will be left in an exposed position if it doesn't pull off the deal with Medeva. Companies would not rush to buy Fisons, even though it is more attractive now."

This is why Fisons may be willing to pay £3 a share or more for Medeva, valuing the company at £900m, compared with a current market price below 250p. It is also why the deal may in the end look more like a merger or a reverse takeover than an outright purchase by Fisons. The stock market would almost certainly take more comfort from a combined company run largely by Medeva executives than one controlled by the Fisons team. Indeed, the outcome of the deal talks will almost certainly hinge partly on how the jobs will be shared out.

But while Fisons has everything to gain, Medeva's motive for the deal is less clear. The fit between products, such as its respiratory products and Fisons' asthma drugs, makes sense. Moreover, Fisons brings a large European sales force, which Medeva lacks since most of its marketing effort is in the US.

Yet in the near term, its sales and earnings will almost certainly be impaired by linking up with Fisons. Pushing up the sales of the combined group will also become a mammoth task that will require the company to find some remarkable new drugs - not an easy job, even for Medeva's talented management.

For these reasons, Medeva will have to drive a hard bargain to justify the deal. It is said to have set a minimum of 280p in the negotiations so far, but its US shareholders - about half the investor base - may demand more. In the end Medeva may find it hard to accept anything less than £3 per share. Fisons may, ultimately, have to scrape together substantially more to clinch the deal.

Even then, the takeover is by no means in the bag. Most analysts give it a 50-50 chance. But if Mr Wallis does not pull it off and his company has to face the future on its own, things may start to look bleak for Fisons.

Start your day with The Independent, sign up for daily news emails
ebooksA year of political gossip, levity and intrigue from the sharpest pen in Westminster
Arts and Entertainment
Under the skin: Sarah Kane in May 1998
theatreThe story behind a new season of Sarah Kane plays
Arts and Entertainment
Preening: Johnny Depp in 'Mortdecai'
filmMortdecai becomes actor's fifth consecutive box office bomb
Bradford City's reward for their memorable win over Chelsea is a trip to face either Sunderland or Fulham (Getty)
Lars Andersen took up archery in his mid thirties
Focus E15 Mothers led a protest to highlight the lack of affordable housing in London
voicesLondon’s housing crisis amounts to an abuse of human rights, says Grace Dent
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Ashdown Group: Client Services Manager - Relationship Management - London

£30000 - £32000 per annum + benefits : Ashdown Group: A highly successful, int...

Recruitment Genius: Credit Controller / Customer Service

£18000 - £20000 per annum: Recruitment Genius: This rapidly expanding business...

Guru Careers: In-House / Internal Recruiter

£25 - 28k + Bonus: Guru Careers: An In-house / Internal Recruiter is needed to...

Recruitment Genius: Tax Assistant

Negotiable: Recruitment Genius: A Tax Assistant is required to join a leading ...

Day In a Page

Syria crisis: Celebrities call on David Cameron to take more refugees as one young mother tells of torture by Assad regime

Celebrities call on David Cameron to take more Syrian refugees

One young mother tells of torture by Assad regime
The enemy within: People who hear voices in their heads are being encouraged to talk back – with promising results

The enemy within

People who hear voices in their heads are being encouraged to talk back
'In Auschwitz you got used to anything'

'In Auschwitz you got used to anything'

Survivors of the Nazi concentration camp remember its horror, 70 years on
Autumn/winter menswear 2015: The uniforms that make up modern life come to the fore

Autumn/winter menswear 2015

The uniforms that make up modern life come to the fore
'I'm gay, and plan to fight military homophobia'

'I'm gay, and plan to fight military homophobia'

Army general planning to come out
Iraq invasion 2003: The bloody warnings six wise men gave to Tony Blair as he prepared to launch poorly planned campaign

What the six wise men told Tony Blair

Months before the invasion of Iraq in 2003, experts sought to warn the PM about his plans. Here, four of them recall that day
25 years of The Independent on Sunday: The stories, the writers and the changes over the last quarter of a century

25 years of The Independent on Sunday

The stories, the writers and the changes over the last quarter of a century
Homeless Veterans appeal: 'Really caring is a dangerous emotion in this kind of work'

Homeless Veterans appeal

As head of The Soldiers' Charity, Martin Rutledge has to temper compassion with realism. He tells Chris Green how his Army career prepared him
Wu-Tang Clan and The Sexual Objects offer fans a chance to own the only copies of their latest albums

Smash hit go under the hammer

It's nice to pick up a new record once in a while, but the purchasers of two latest releases can go a step further - by buying the only copy
Geeks who rocked the world: Documentary looks back at origins of the computer-games industry

The geeks who rocked the world

A new documentary looks back at origins of the computer-games industry
Belle & Sebastian interview: Stuart Murdoch reveals how the band is taking a new direction

Belle & Sebastian is taking a new direction

Twenty years ago, Belle & Sebastian was a fey indie band from Glasgow. It still is – except today, as prime mover Stuart Murdoch admits, it has a global cult following, from Hollywood to South Korea
America: Land of the free, home of the political dynasty

America: Land of the free, home of the political dynasty

These days in the US things are pretty much stuck where they are, both in politics and society at large, says Rupert Cornwell
A graphic history of US civil rights – in comic book form

A graphic history of US civil rights – in comic book form

A veteran of the Fifties campaigns is inspiring a new generation of activists
Winston Churchill: the enigma of a British hero

Winston Churchill: the enigma of a British hero

A C Benson called him 'a horrid little fellow', George Orwell would have shot him, but what a giant he seems now, says DJ Taylor
Growing mussels: Precious freshwater shellfish are thriving in a unique green project

Growing mussels

Precious freshwater shellfish are thriving in a unique green project